Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with serious and rare diseases. The company's product candidate is ARIKAYCE for the treatment of mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options in a refractory setting. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone908-977-9900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$9.84 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/1/2019 (Estimated)
OptionableOptionable
Insmed (NASDAQ:INSM) Frequently Asked Questions
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed Incorporated (NASDAQ:INSM) released its quarterly earnings results on Friday, February, 22nd. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, missing analysts' consensus estimates of ($1.11) by $0.06. The biopharmaceutical company earned $9.84 million during the quarter, compared to analysts' expectations of $5.01 million. View Insmed's Earnings History.
When is Insmed's next earnings date?
What price target have analysts set for INSM?
7 Wall Street analysts have issued 12 month target prices for Insmed's stock. Their predictions range from $22.00 to $44.00. On average, they expect Insmed's stock price to reach $37.00 in the next twelve months. This suggests a possible upside of 30.7% from the stock's current price. View Analyst Price Targets for Insmed.
What is the consensus analysts' recommendation for Insmed?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insmed.
Has Insmed been receiving favorable news coverage?
News headlines about INSM stock have been trending somewhat negative on Tuesday, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insmed earned a media sentiment score of -1.5 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near term.
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), SAGE Therapeutics (SAGE), Loxo Oncology (LOXO), Dr.Reddy's Laboratories (RDY), Perrigo (PRGO), Marina Biotech (MRNA), Catalent (CTLT), Amarin (AMRN), Nektar Therapeutics (NKTR), Alkermes (ALKS), United Therapeutics (UTHR) and GALAPAGOS NV/S (GLPG).
What other stocks do shareholders of Insmed own?
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- Mr. William H. Lewis, Pres, CEO & Chairman (Age 50)
- Mr. Paolo Tombesi, Chief Financial Officer (Age 55)
- Ms. Christine A. Pellizzari, Chief Legal Officer (Age 51)
- Mr. Roger Adsett, Chief Commercial Officer (Age 50)
- Dr. Paul D. Streck, Advisor (Age 55)
Who are Insmed's major shareholders?
Insmed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Foresite Capital Management IV LLC (2.56%), Northern Trust Corp (1.22%), Geode Capital Management LLC (1.12%), Geode Capital Management LLC (1.12%) and Bellevue Group AG (1.05%). Company insiders that own Insmed stock include Alfred Altomari, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View Institutional Ownership Trends for Insmed.
Which major investors are selling Insmed stock?
INSM stock was sold by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Northern Trust Corp, TD Asset Management Inc., Los Angeles Capital Management & Equity Research Inc., Squarepoint Ops LLC, California Public Employees Retirement System and MetLife Investment Advisors LLC. Company insiders that have sold Insmed company stock in the last year include Alfred Altomari, Donald J Hayden Jr and Orlov S Nicole Schaeffer. View Insider Buying and Selling for Insmed.
Which major investors are buying Insmed stock?
INSM stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Bellevue Group AG, Foresite Capital Management IV LLC, Geode Capital Management LLC, Geode Capital Management LLC and Hudson Bay Capital Management LP. Company insiders that have bought Insmed stock in the last two years include Christine A Pellizzari, Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen and William Lewis. View Insider Buying and Selling for Insmed.
How do I buy shares of Insmed?
Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
One share of INSM stock can currently be purchased for approximately $28.30.
How big of a company is Insmed?
Insmed has a market capitalization of $2.19 billion and generates $9.84 million in revenue each year. The biopharmaceutical company earns $-324,280,000.00 in net income (profit) each year or ($4.17) on an earnings per share basis.
What is Insmed's official website?
How can I contact Insmed?
Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]
MarketBeat Community Rating for Insmed (NASDAQ INSM)
MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.
